Hostname: page-component-8448b6f56d-xtgtn Total loading time: 0 Render date: 2024-04-24T08:28:38.361Z Has data issue: false hasContentIssue false
  • English
  • Français

Open-label olanzapine in obsessive-compulsive disorder refractory to antidepressant treatment

Published online by Cambridge University Press:  16 April 2020

M.A. Crocq ,
Ph. Leclercq ,
M.S. Guillon  and
P.E. Bailey
M.A. Crocq*
Affiliation:
Centre hospitalier, BP 29, 68250 Rouffach, France
Ph. Leclercq
Affiliation:
Centre hospitalier, BP 29, 68100Mulhouse, France
M.S. Guillon
Affiliation:
Centre hospitalier, BP 29, 68250 Rouffach, France
P.E. Bailey
Affiliation:
Centre hospitalier, BP 29, 68250 Rouffach, France
*
*Corresponding author. E-mail address:macrocq@forenap.asso.fr (M.A. Crocq).

Abstract

An abstract is not available for this content so a preview has been provided. As you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'

Keywords

OlanzapineObsessive–compulsive disorderAugmentation therapyTreatment–unresponsive OCD
Type
Letter to the editor
Information
European Psychiatry , Volume 17 , Issue 5 , September 2002 , pp. 296 - 297
Copyright
Copyright © European Psychiatric Association 2002

References

Marazziti, DPallanti, S. Effectiveness of olanzapine treatment for severe obsessive–compulsive disorder. Am J Psychiaty 1999;156:1834–5.Google ScholarPubMed
Marusic, AFarmer, A. Antidepressant augmentation with low-dose olanzapine in obsessive–compulsive disorder. Br J Psychiatry 2000;177:567.CrossRefGoogle ScholarPubMed
Weiss, ELPotenza, MNMcDougle, CJEpperson, CN. Olan-zapine addition in obsessive–compulsive disorder refractory to selective serotonin reuptake inhibitors: an open-label case series. J Clin Psychiatry 1999;60:524–7.CrossRefGoogle Scholar
Koran, LMRingold, MDElliott, MA. Olanzapine augmentation for treatment-resistant obsessive–compulsive disorder. J Clin Psychiatry 2000;61:514.Google ScholarPubMed
Bogetto, FBellino, SVaschetto, PZiero, S. Olanzapine augmentation of obsessive–compulsive disorder: a 12-week open trial. Psychiatry Res 2000;96:91–8.CrossRefGoogle ScholarPubMed
McDougle, CJEpperson, CNPelton, GHWasylink, SPrice, LH. A double-blind, placebo-controlled study of risperi-done addition in serotonin reuptake inhibitor-refractory obsessive-compulsive disorder. Arch Gen Psychiatry 2000;57:794–801.Google Scholar
McDougle, CJGoodman, WKLeckman, JFLee, NCHeninger, GRPrice, LH. Haloperidol addition in fluvoxamine-refractory obsessive-compulsive disorder. A double-blind, placebo-controlled study in patients with and without tics. Arch Gen Psychiatry 1994;51:302–8.Google ScholarPubMed
Bymaster, FPCalligaro, DOFalcone, JFMarsh, RDMoore, NATye, NC et al. Radioreceptor binding profile of the atypical antipsychotic olanzapine. Neuropsychopharmacology 1996;14:87–96.CrossRefGoogle ScholarPubMed
Pauwels, PJ. 5-HT 1B/D receptor antagonists. Gen Pharmacol 1997;29:293–303.Google ScholarPubMed
Submit a response

Comments

No Comments have been published for this article.